MYC and breast cancer: While rapid drug metabolism limits the efficacy of 10058-F4 as an antitumor agent for solid tumors [28], its use in vitro showed that inhibiting MYC in antiestrogen resistant breast cancer cells confirmed the essential role of MYC activation in driving this phenotype.